Outputs (67)

Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function (2025)
Journal Article
Dellschaft, N., Murray, K., Ren, Y., Marciani, L., Gowland, P., Spiller, R., & Hoad, C. (2025). Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function. Neurogastroenterology and Motility, https://doi.org/10.1111/nmo.14999

Background
The human colon receives 2 L of fluid daily. Small changes in the efficacy of absorption can lead to altered stool consistency with diarrhea or constipation. Drugs and formulations can also alter colonic water, which can be assessed using... Read More about Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function.

Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation (2024)
Journal Article
Aliyu, A., Dellschaft, N., Hoad, C., Williams, H., Gaudoin, E., Sulaiman, S., Crooks, C., Gowland, P., Alexia, A., Lange, R., Bois de Fer, B., Corsetti, M., Marciani, L., & Spiller, R. (2024). Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation. Clinical Pharmacology and Therapeutics, https://doi.org/10.1002/cpt.3532

Bisacodyl is a widely used laxative that stimulates both motility and secretion. Our aim was to exploit the unique capabilities of MRI to define bisacodyl's mode of action. Two placebo-controlled cross-over trials were performed, one using a single d... Read More about Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation.

Combined magnetic resonance imaging, high resolution manometry and a randomised trial of bisacodyl versus hyoscine shows the significance of an enlarged colon in constipation: the RECLAIM study (2024)
Journal Article
Wilkinson-Smith, V., Scott, M., Menys, A., Wiklendt, L., MARCIANI, L., Atkinson, D., Sansone, S., Zdanavciene, A., Coupland, C., Knowles, C., Dinning, P., Taylor, S., Gowland, P., Hoad, C., Corsetti, M., & Spiller, R. (2025). Combined magnetic resonance imaging, high resolution manometry and a randomised trial of bisacodyl versus hyoscine shows the significance of an enlarged colon in constipation: the RECLAIM study. Gut, 74(1), 35-44. https://doi.org/10.1136/gutjnl-2024-332755

Background
Colonic motility in constipation can be assessed non-invasively using MRI.

Objective
To compare MRI with high resolution colonic manometry (HRCM) for predicting treatment response.

Design
Part 1: 44 healthy volunteers (HV), 43... Read More about Combined magnetic resonance imaging, high resolution manometry and a randomised trial of bisacodyl versus hyoscine shows the significance of an enlarged colon in constipation: the RECLAIM study.

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. (2023)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C., Marciani, L., Spiller, R., Crooks, C., Hill, T., Menys, A., Mainz, J. G., Barr, H., Gowland, P. A., Major, G., & Smyth, A. R. (2023). A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. NIHR Open Research, 3(65), 1-16. https://doi.org/10.3310/nihropenres.13510.1

Background

People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung fun... Read More about A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes..

Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial (2023)
Journal Article
Gunn, D., Topan, R., Barnard, L., Fried, R., Holloway, I., Brindle, R., Corsetti, M., Scott, M., Farmer, A., Kapur, K., Sanders, D., Eugenicos, M., Trudgill, N., Whorwell, P., Mclaughlin, J., Akbar, A., Houghton, L., Dinning, P. G., Aziz, Q., Ford, A. C., …Spiller, R. (2023). Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology and Therapeutics, 57(11), 1258-1271. https://doi.org/10.1111/apt.17426

Summary: Background: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS‐D). Aim: To conduct a 12‐week parallel group, randomised, double‐blind, placebo‐controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.)... Read More about Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.

Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery (2022)
Journal Article
Jalanka, J., Gunn, D., Singh, G., Krishnasamy, S., Lingaya, M., Crispie, F., Finnegan, L., Cotter, P., James, L., Nowak, A., Major, G., & Spiller, R. C. (2022). Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery. Gut, https://doi.org/10.1136/gutjnl-2021-326828

Objectives: Persistent bowel dysfunction following gastroenteritis (postinfectious (PI)-BD) is well recognised, but the associated changes in microbiota remain unclear. Our aim was to define these changes after gastroenteritis caused by a single orga... Read More about Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery.

The serotonin receptor 3E variant is a risk factor for female IBS-D (2022)
Journal Article
Fritz, N., Berens, S., Dong, Y., Martínez, C., Schmitteckert, S., Houghton, L. A., Goebel-Stengel, M., Wahl, V., Kabisch, M., Götze, D., D'Amato, M., Zheng, T., Röth, R., Mönnikes, H., Tesarz, J., Engel, F., Gauss, A., Raithel, M., Andresen, V., Keller, J., …Niesler, B. (2022). The serotonin receptor 3E variant is a risk factor for female IBS-D. Journal of Molecular Medicine, 100, 1617–1627. https://doi.org/10.1007/s00109-022-02244-w

Irritable bowel syndrome (IBS) is a gut-brain disorder of multifactorial origin. Evidence of disturbed serotonergic function in IBS accumulated for the 5-HT3 receptor family. 5-HT3Rs are encoded by HTR3 genes and control GI function, and peristalsis... Read More about The serotonin receptor 3E variant is a risk factor for female IBS-D.

Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the Gastrointestinal Tract in Human Volunteers (2022)
Journal Article
Sulaiman, S., Gershkovich, P., Hoad, C. L., Calladine, M., Spiller, R. C., Stolnik, S., & Marciani, L. (2022). Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the Gastrointestinal Tract in Human Volunteers. Pharmaceutics, 14(2), Article 270. https://doi.org/10.3390/pharmaceutics14020270

Oral specially coated formulations have the potential to improve treatment outcomes of a range of diseases in distal intestinal tract whilst limiting systemic drug absorption and adverse effects. Their development is challenging, partly because of li... Read More about Application of In Vivo MRI Imaging to Track a Coated Capsule and Its Disintegration in the Gastrointestinal Tract in Human Volunteers.

Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders (2021)
Journal Article
Eijsbouts, C., Zheng, T., Kennedy, N. A., Bonfiglio, F., Anderson, C. A., Moutsianas, L., Holliday, J., Shi, J., Shringarpure, S., 23andMe Research Team, Voda, A.-I., The Bellygenes Initiative, Farrugia, G., Franke, A., Hübenthal, M., Abecasis, G., Zawistowski, M., Skogholt, A. H., Ness-Jensen, E., Hveem, K., …Parkes, M. (2021). Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nature Genetics, 53(11), 1543-1552. https://doi.org/10.1038/s41588-021-00950-8

Irritable bowel syndrome (IBS) results from disordered brain–gut interactions. Identifying susceptibility genes could highlight the underlying pathophysiological mechanisms. We designed a digestive health questionnaire for UK Biobank and combined ide... Read More about Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders.

Small bowel water content assessed by MRI in health and disease: a collation of single-centre studies (2021)
Journal Article
Dellschaft, N., Hoad, C., Marciani, L., Gowland, P., & Spiller, R. (2022). Small bowel water content assessed by MRI in health and disease: a collation of single-centre studies. Alimentary Pharmacology and Therapeutics, 55(3), 327-338. https://doi.org/10.1111/apt.16673

Background: New developments in MRI have allowed the non-invasive, accurate measurement of the small bowel water content (SBWC). Aims: To collate studies measuring SBWC following ingestion of a range of foods in both health and disease to provide dat... Read More about Small bowel water content assessed by MRI in health and disease: a collation of single-centre studies.